Additionally, GAs in KRAS, including KRAS G12C mutations, were more frequently seen in KMT2Ar AML, which has more clinical implications in solid malignancies like non-small-cell lung cancer. This evidence concerns the gene KRAS and non-small cell lung carcinoma.